Neuroleptic Malignant Syndrome (NMS)

Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening neurological and medical emergency most commonly associated with the use of antipsychotic medications. It is characterized by severe muscle rigidity, hyperthermia, altered mental status, and autonomic instability.

The syndrome is most frequently associated with high-dose antipsychotic therapy, potent antipsychotic agents such as haloperidol, rapid dose escalation, and administration through intramuscular or intravenous routes. Early recognition and immediate intervention are critical because delayed treatment can result in severe complications and death.

Epidemiology

Neuroleptic malignant syndrome is an uncommon adverse effect of antipsychotic medications but remains one of the most serious complications of psychopharmacological treatment.

The condition may occur at any age and in both sexes. Although most commonly associated with first-generation antipsychotics, NMS can also occur with second-generation antipsychotics and other dopamine-blocking agents.

Risk Factors

Medication-Related Risk Factors

• High-dose antipsychotic therapy

• Rapid dose escalation

• Use of potent antipsychotics such as haloperidol

• Intramuscular administration of antipsychotics

• Intravenous administration of antipsychotics

• Concurrent use of multiple antipsychotic medications

• Abrupt withdrawal of dopaminergic agents

Patient-Related Risk Factors

• Previous episode of NMS

• Dehydration

• Agitation

• Catatonia

• Physical exhaustion

• Organic brain disease

• Acute medical illness

Pathophysiology

The exact mechanism of NMS is not fully understood. The syndrome is believed to result primarily from central dopamine receptor blockade, particularly within the hypothalamus and basal ganglia.

This dopamine blockade leads to:

• Impaired thermoregulation

• Severe muscle rigidity

• Altered consciousness

• Autonomic nervous system dysfunction

• Increased skeletal muscle metabolism

Muscle breakdown may occur, resulting in elevated creatine kinase levels and potential complications such as rhabdomyolysis and acute kidney injury.

Clinical Presentation

Symptoms usually develop over hours to several days following initiation, dose escalation, or administration of antipsychotic medications.

Symptoms

• Fever

• Muscle stiffness

• Difficulty swallowing

• Reduced speech or mutism

• Confusion

• Drowsiness

• Excessive sweating

• Generalized weakness

Clinical Signs

Major Signs

• Severe muscle rigidity

• Hyperthermia (fever)

• Altered consciousness

Additional Signs

• Mutism

• Dysphagia

• Diaphoresis

• Tachycardia

• Labile blood pressure

• Tremor

• Incontinence

Autonomic Instability

• Tachycardia

• Blood pressure fluctuations

• Excessive sweating

• Tachypnea

Diagnostic Criteria

Neuroleptic malignant syndrome is a clinical diagnosis based on:

Essential Features

• Recent exposure to antipsychotic medication or dopamine antagonist

• Severe muscle rigidity

• Elevated body temperature

• Altered mental status

Supportive Features

• Tachycardia

• Labile blood pressure

• Diaphoresis

• Tremor

• Dysphagia

• Incontinence

• Elevated serum creatine kinase

• Leukocytosis

The diagnosis is strengthened by the exclusion of alternative causes of fever, altered consciousness, and muscle rigidity.

Differential Diagnosis

Psychiatric Disorders

• Malignant catatonia

• Severe agitation associated with psychosis

Neurological Disorders

• Meningitis

• Encephalitis

• Status epilepticus

• Stroke

Drug-Related Conditions

• Serotonin syndrome

• Anticholinergic toxicity

• Drug intoxication

• Drug withdrawal syndromes

Medical Conditions

• Sepsis

• Heat stroke

• Thyrotoxic crisis

• Pheochromocytoma

Investigations

Laboratory Investigations

Full Blood Count

May demonstrate:

• Leukocytosis

Serum Creatine Kinase (CK)

Laboratory evidence of muscle injury includes:

• Increased creatine kinase levels

Additional Laboratory Tests

• Renal function tests

• Liver function tests

• Serum electrolytes

• Arterial blood gas analysis when indicated

• Urinalysis

Monitoring Investigations

• Vital signs monitoring

• Fluid balance monitoring

• Cardiac monitoring

• Oxygen saturation monitoring

Management

Neuroleptic malignant syndrome is a medical and psychiatric emergency requiring immediate intervention.

The goals of treatment are to:

• Prevent death and serious complications

• Stabilize vital functions

• Reverse hyperthermia

• Reduce muscle rigidity

• Correct dehydration and metabolic abnormalities

• Prevent organ failure

Immediate Management

Stop Antipsychotic Medication

All antipsychotic medications should be discontinued immediately.

Intensive Care Management

Patients require urgent transfer to a high-dependency unit or intensive care unit for close monitoring and supportive management.

Supportive Measures

Supportive treatment should be initiated immediately and includes:

• Bed rest

• Intravenous fluid replacement

• Correction of electrolyte abnormalities

• Monitoring of vital signs

• Prevention of complications

Control of Hyperthermia

Hyperthermia should be managed by:

• Rapid cooling measures

• Tepid water spray

• External cooling methods

• Adequate fluid replacement

Respiratory Support

Patients with severe respiratory compromise may require:

• Oxygen therapy

• Ventilator support

• Endotracheal intubation

Pharmacological Treatment

Use one of the following:

• Diazepam (IV) 10 mg

OR

• Lorazepam (IM/IV) 2 mg for immediate sedative or hypnotic action. If there is no response, a second dose may be administered.

OR

• Bromocriptine (PO) 2.5 mg every 8 hours.

Principles of Pharmacological Treatment

• Medications should be administered alongside intensive supportive care.

• Continuous monitoring is essential.

• Treatment should be individualized according to clinical response.

• Early intervention improves outcomes.

Management of Complications

Rhabdomyolysis

• Aggressive hydration

• Monitoring of creatine kinase levels

• Monitoring of renal function

Acute Kidney Injury

• Fluid management

• Renal function monitoring

• Specialist consultation when required

Respiratory Failure

• Oxygen therapy

• Mechanical ventilation where indicated

Cardiovascular Instability

• Continuous cardiac monitoring

• Management of blood pressure abnormalities

• Intensive care support

Referral

Immediate referral is required for all patients with suspected neuroleptic malignant syndrome.

Urgent referral should include:

• Intensive care unit assessment

• Psychiatric consultation

• Internal medicine consultation

• Neurology consultation when indicated

Complications

Neuromuscular Complications

• Severe muscle injury

• Rhabdomyolysis

• Persistent rigidity

Renal Complications

• Acute kidney injury

• Renal failure

Cardiovascular Complications

• Arrhythmias

• Blood pressure instability

• Cardiovascular collapse

Respiratory Complications

• Respiratory failure

• Aspiration pneumonia

Other Complications

• Disseminated intravascular coagulation

• Multiorgan failure

• Death

Prognosis

The prognosis depends largely on early recognition and prompt treatment. Most patients recover completely when NMS is identified early and managed appropriately.

Delayed diagnosis and treatment increase the risk of severe complications, prolonged hospitalization, permanent disability, and death.

Prevention

• Use the lowest effective antipsychotic dose.

• Avoid rapid dose escalation.

• Monitor high-risk patients closely.

• Maintain adequate hydration.

• Exercise caution when using potent antipsychotic medications.

• Monitor patients receiving intramuscular or intravenous antipsychotic therapy.

• Recognize early warning signs promptly.

Special Considerations

• Neuroleptic malignant syndrome is a clinical emergency requiring immediate treatment.

• Intensive care unit management is usually required.

• Antipsychotic medications should be stopped immediately.

• Supportive measures, including bed rest, rapid cooling with tepid water spray, and fluid replacement, should be initiated without delay.

• Ventilator support or endotracheal intubation may be required in patients with severe breathing difficulties.

• Early recognition and aggressive supportive management significantly improve outcomes.